Preparation and In Vitro and In Vivo Evaluation of a Testosterone Film Forming Gel for the Treatment of Hypoactive Sexual Desire Disorder in Women

被引:3
|
作者
Zeng, Jia [1 ]
Xie, Tan-Fang [2 ]
Huang, Ting [1 ]
Li, Fang [1 ]
Wang, Zhi-Ping [2 ]
Feng, Ling-Lin [1 ]
机构
[1] Shanghai Engineer & Technol Res Ctr Reprod Hlth D, Shanghai Inst Biomed & Pharmaceut Technol, NHC Key Lab Reprod Regulat, Shanghai 200032, Peoples R China
[2] Guangxi Univ Chinese Med, Dept Pharmaceut, Key Lab Common Technol Tradit Chinese Med Prepara, Nanning 530020, Peoples R China
关键词
testosterone; film forming gel; Transcutol P; in vitro; in vivo; SURGICALLY MENOPAUSAL WOMEN; POSTMENOPAUSAL WOMEN; SKIN PERMEATION; UNITED-STATES; DELIVERY; REAPPRAISAL; FORMULATION; PREVALENCE; TRANSCUTOL; MOTIVATION;
D O I
10.1208/s12249-021-02201-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hypoactive sexual desire disorder (HSDD) is one of the most common sexual complaints in women. Currently, there is an unmet need for a drug treatment for this disorder. The purpose of this study was to develop a testosterone (TS) film forming gel used for women to treat HSDD by measuring the tackiness, peel adhesion force, tensile strength, and elasticity of the formulation. Diethylene glycol monoethyl ether (Transcutol P), an efficient penetration enhancer, was added to the optimized formulation and the transdermal permeation characteristics in vitro were studied using Franz-diffusion cells. The quantitative determination of TS was performed by high-performance liquid chromatography (HPLC). After 24 h, Transcutol P at 3% had the largest cumulative amount of drug and enhancement ratio of TS of 75.14 mu g/cm(2) and 2.82, respectively. After the screening of film forming polymers and penetration enhancers, the optimal formulation was as follows: glycerol (1%, w/w); 12.5% sodium carboxymethylcellulose (CMC-Na) aqueous solution (0.5%, w/w); 2.5% Carbomer ethanol solution (0.5%, w/w); Transcutol P ethanol solution (3%, w/w) containing 0.5% TS; and 8% Poly vinyl alcohol (PVA) aqueous solution (30%, w/w). The optimized film forming gel had good uniformity and the release of TS in vitro was close to 100% within 24 h. In vivo studies showed the formulations had optimal area under blood drug concentration curve values in the order of 3% Transcutol P > 1% Transcutol P > 5% Transcutol P > control preparation. The formulation with 3% Transcutol P provided the highest permeation effect both in vitro and in vivo. The safety of this formulation was further evaluated with a skin irritation test. It could effectively improve the rabbit skin irritation observed with a marketed transdermal patch Androderm (R). The present study provides a promising approach for the development of a novel TS film forming gel for the treatment of HSDD in women.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women
    Dhanuka, Ida
    Simon, James A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (16) : 2523 - 2529
  • [22] The Presentation of Hypoactive Sexual Desire Disorder in Premenopausal Women
    Maserejian, Nancy N.
    Shifren, Jan L.
    Parish, Sharon J.
    Braunstein, Glenn D.
    Gerstenberger, Eric P.
    Rosen, Raymond C.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (10) : 3439 - 3448
  • [23] Testosterone therapy in women: its role in the management of hypoactive sexual desire disorder
    R T Abdallah
    J A Simon
    International Journal of Impotence Research, 2007, 19 : 458 - 463
  • [24] An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder
    Cipriani, Sarah
    Alfaroli, Chiara
    Maseroli, Elisa
    Vignozzi, Linda
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (01) : 15 - 21
  • [25] Hypoactive sexual desire disorder in postmenopausal women
    Nappi, Rosselia E.
    Wawra, Kathrin
    Schmitt, Sonja
    GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (06) : 318 - 323
  • [26] A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disordera
    White, William B.
    Grady, Deborah
    Giudice, Linda C.
    Berry, Scott M.
    Zborowski, Joanne
    Snabes, Michael C.
    AMERICAN HEART JOURNAL, 2012, 163 (01) : 27 - 32
  • [28] Hypoactive Sexual Desire Disorder in Premenopausal Women: Case Studies
    Miner, Martin
    Sadovsky, Richard
    Buster, John E.
    POSTGRADUATE MEDICINE, 2012, 124 (01) : 94 - 103
  • [29] Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
    Pettigrew, Jessica A.
    Novick, Andrew M.
    JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2021, 66 (06) : 740 - 748
  • [30] Efficacy and safety of testosterone in the treatment of hypoactive sexual desire in women: what does the evidence say?
    de la Hoz, Franklin Jose Espitia
    REVISTA INTERNACIONAL DE ANDROLOGIA, 2023, 21 (01):